Manufacturer: CSL manufactures Daivobet.


The uses of Daivobet include:
Daivobet® ointment is indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy in adult patients 18 years and older.


Daivobet® ointment is indicated FOR TOPICAL USE ONLY and NOT FOR OPHTHALMIC USE.

All psoriasis-affected areas treated with Daivobet® should be, where possible, protected from direct sunlight and UV-light with items of clothing. Topical calcipotriol should only be used with UV radiation if the physician and patient consider that the potential benefits outweigh the potential risks. The potential phototoxic effects of Daivobet® over long term exposure have not been fully investigated.


Daivobet® ointment should be applied topically to the affected area once daily. The maximum daily dose should not exceed 15 grams.

The maximum recommended weekly dose of Daivobet® ointment is 100 g/week.

The treated area should not be more than 30% of the body surface.

The recommended treatment period of Daivobet® ointment is 4 weeks. At the completion of the treatment period, repeated treatment with Daivobet® ointment can be initiated under medical supervision. There is no clinical experience with Daivobet® Ointment beyond 52 weeks.


Daivobet® ointment is not recommended for use in children and adolescents below the age of 18 years.